The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
Open accessAbstract
Vascular endothelial growth factor A (VEGFA; hereafter referred to as VEGF) is a key regulator of physiological and pathological angiogenesis. Two families of VEGF isoforms are generated by alternate splice-site selection in the terminal exon. Proximal splice-site selection (PSS) in exon 8 results in pro-angiogenic VEGFxxx isoforms (xxx is the number of amino acids), whereas distal splice-site selection (DSS) results in anti-angiogenic VEGFxxxb isoforms. To investigate control of PSS and DSS, we investigated the regulation of isoform expression by extracellular growth factor administration and intracellular splicing factors. In primary epithelial cells VEGFxxxb formed the majority of VEGF isoforms (74%). IGF1, and TNFα treatment favoured PSS (increasing VEGFxxx) whereas TGFβ1 favoured DSS, increasing VEGFxxxb levels. TGFβ1 induced DSS selection was prevented by inhibition of p38 MAPK and the Clk/sty (CDC-like kinase, CLK1) splicing factor kinase family, but not ERK1/2. Clk phosphorylates SR protein splicing factors ASF/SF2, SRp40 and SRp55. To determine whether SR splicing factors alter VEGF splicing, they were overexpressed in epithelial cells, and VEGF isoform production assessed. ASF/SF2, and SRp40 both favoured PSS, whereas SRp55 upregulated VEGFxxxb (DSS) isoforms relative to VEGFxxx. SRp55 knockdown reduced expression of VEGF165b. Moreover, SRp55 bound to a 35 nucleotide region of the 3′UTR immediately downstream of the stop codon in exon 8b. These results identify regulation of splicing by growth and splice factors as a key event in determining the relative pro-versus anti-angiogenic expression of VEGF isoforms, and suggest that p38 MAPK-Clk/sty kinases are responsible for the TGFβ1-induced DSS selection, and identify SRp55 as a key regulatory splice factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., & Leung, D. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1806 · Cited by 1,365
Understanding alternative splicing: towards a cellular code
Matlin, A. J., Clark, F., & Smith, C. W. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1645 · Cited by 1,305
A Conditionally Immortalized Human Podocyte Cell Line Demonstrating Nephrin and Podocin Expression
Saleem, M. A., O’Hare, M. J., Reiser, J., Coward, R. J., Inward, C. D., Farren, T., Xing, C. Y., Ni, L., Mathieson, P. W., & Mundel, P. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133630 · Cited by 1,120
Self-citation
Cited by
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
David, C. J., & Manley, J. L. (2010) · Genes & Development · doi:10.1101/gad.1973010 · Cited by 814
Hallmarks of alternative splicing in cancer
Oltean, S., & Bates, D. O. (2014) · Oncogene · doi:10.1038/onc.2013.533 · Cited by 664
Self-citationVEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Self-citationMolecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Peach, C. J., Mignone, V. W., Arruda, M. A., Alcobia, D. C., Hill, S. J., Kilpatrick, L. E., & Woolard, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041264 · Cited by 512
Self-citationLee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis
Corliss, B. A., Azimi, M. S., Munson, J. M., Peirce, S. M., & Murfee, W. L. (2016) · Microcirculation · doi:10.1111/micc.12259 · Cited by 356
Metals and Mechanisms of Carcinogenesis
Chen, Q. Y., DesMarais, T., & Costa, M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021031 · Cited by 336
The molecular mechanisms of hemodialysis vascular access failure
Brahmbhatt, A., Remuzzi, A., Franzoni, M., & Misra, S. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.019 · Cited by 259
WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing
Amin, E. M., Oltean, S., Hua, J., Gammons, M. V. R., Hamdollah-Zadeh, M., Welsh, G. I., Cheung, M.-K., Ni, L., Kase, S., Rennel, E. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.016 · Cited by 253
Self-citationVascular normalisation as the stepping stone into tumour microenvironment transformation
Magnussen, A. L., & Mills, I. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01330-z · Cited by 146
Zaytseva, Y. Y., Elliott, V. A., Rychahou, P., Mustain, W. C., Kim, J. T., Valentino, J., Gao, T., O’Connor, K. L., Neltner, J. M., Lee, E. Y., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu042 · Cited by 104
Boudria, A., Abou Faycal, C., Jia, T., Gout, S., Keramidas, M., Didier, C., Lemaître, N., Manet, S., Coll, J.-L., Toffart, A.-C., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0486-7 · Cited by 53
ProMetheusDB: An In-Depth Analysis of the High-Quality Human Methyl-proteome
Massignani, E., Giambruno, R., Maniaci, M., Nicosia, L., Yadav, A., Cuomo, A., Raimondi, F., & Bonaldi, T. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100243 · Cited by 9
Metadata
- Authors
- Nowak, D. G., Woolard, J., Amin, E. M., Konopatskaya, O., Saleem, M. A., Churchill, A. J., Ladomery, M. R., Harper, S. J., & Bates, D. O.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2008-10-15
- Volume
- 121
- Issue
- 20
- Pages
- 3487-3495
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W1992049575
- Cited by
- 339
- References
- 60
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.